Test Price
3,200 AED✅ Home Collection Available
Next‑Generation Sequencing (NGS) Glaucoma Genetic Panel in the UAE | 3,200 AED | DHA Licensed
Executive Summary & Core Metrics
Precision Genetic Risk Stratification for Glaucoma
- 99.9% analytical sensitivity via NGS with orthogonal Sanger confirmation.
- VIP mobile phlebotomy & temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Post‑report telegenetics consultation with a DHA‑licensed Consultant Medical Geneticist.
- Insurance pre‑authorization support via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
This advanced NGS glaucoma genetic panel analyzes over 20 curated genes (including MYOC, OPTN, CYP1B1, WDR36, LTBP2, FOXC1) with full exon coverage and copy number variant detection. Every pathogenic or likely pathogenic variant is validated by orthogonal Sanger sequencing, providing definitive genotype information for primary open‑angle, angle‑closure, and congenital glaucoma. The final report is interpreted in accordance with ACMG/AMP guidelines and delivered with a personalised clinical summary.
| Feature | Our NGS Glaucoma Panel | Standard Single‑Gene Sanger Test |
|---|---|---|
| Methodology | NGS + Sanger validation, full gene coverage & CNV analysis | Sanger sequencing of one gene (e.g., MYOC only) |
| Genes Analysed | >20 comprehensive genes (incl. MYOC, OPTN, CYP1B1, LTBP2, WDR36, FOXC1) | 1 gene |
| Turnaround Time | 45 working days | ~30 working days |
| Analytical Sensitivity | 99.9% (NGS & Sanger confirmation) | >99% (Sanger) |
| Price (AED) | 3,200 | ~1,500 |
| Ideal For | Definitive risk assessment, familial screening, research | Limited familial variant confirmation |
Physician Insight & Safety Protocols
“Genetic testing for glaucoma provides invaluable insight for early intervention and family counseling. However, results must be correlated with intraocular pressure measurements, optic nerve head imaging, and a detailed family history to formulate a safe, individualised management plan. The NGS panel’s comprehensive coverage ensures we leave no actionable variant undiscovered.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Important – Do Not Discontinue Glaucoma Medications Abruptly
Prostaglandin analogues, beta‑blockers, carbonic anhydrase inhibitors, and other prescribed ocular hypotensives must not be stopped or modified without consulting your treating ophthalmologist. Sudden cessation can cause irreversible optic nerve damage. Continue your medications as directed; genetic testing is an adjunct, not a substitute for ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Inability to provide informed written consent (mandatory consent form for genetic testing per Federal Decree-Law No. 4 of 2016).
- Known coagulopathy or bleeding disorder incompatible with venipuncture.
- Active systemic infection or unstable cardiovascular status – defer sample collection until clinically stable.
- Emergency red flags: sudden profound vision loss, acute eye pain with nausea/vomiting, or seeing halos around lights – seek immediate emergency ophthalmic care; do not wait for genetic test results.
- Genetic testing on minors requires valid parental consent, complying with UAE Personal Data Protection Law (PDPL) and health data regulations.
Patient FAQ & Clinical Guidance
1. What is the turnaround time for my glaucoma genetic test results?
Short answer: 45 working days from sample receipt, including rigorous Sanger confirmation.
The sample undergoes NGS with bioinformatic analysis, and every potentially pathogenic variant is independently confirmed by orthogonal Sanger sequencing. This dual‑platform approach guarantees 99.9% analytical sensitivity before the final clinical report is issued by our DHA‑licensed laboratory. You will also receive a post‑report telegenetics consultation to explain your results.
2. Is fasting required before the blood draw?
Short answer: No fasting is necessary; maintain normal hydration and diet.
You may eat and drink as usual. Wear a short‑sleeved shirt for easy access to the antecubital fossa. The sample is transported under refrigerated conditions to preserve DNA integrity. Do not freeze the sample. VIP mobile phlebotomy is available daily from 8 AM to 11 PM for your convenience.
3. Which genes are included and how reliable are the results?
Short answer: Over 20 established glaucoma genes, including MYOC, OPTN, CYP1B1, WDR36, LTBP2, FOXC1, with >99.9% analytical sensitivity.
Our dual‑platform methodology eliminates false‑positive calls and provides definitive genotype information. The final report adheres to ACMG/AMP guidelines and includes a comprehensive clinical interpretation by our consultant medical geneticist. This panel is suitable for diagnostic confirmation, presymptomatic testing, and familial risk assessment.
4. Can this test help if I already have a diagnosis of glaucoma?
Short answer: Yes, it can identify the underlying genetic cause and guide treatment decisions.
Discovering a pathogenic variant in genes like MYOC or OPTN can inform prognosis, predict response to therapy, and enable targeted screening of at‑risk family members. Your ophthalmologist can use this information to tailor a personalised management plan that may include more frequent monitoring or earlier surgical intervention.
5. How do I schedule a home collection or check insurance coverage?
Short answer: Contact us via WhatsApp at +971 54 548 8731.
Our patient coordination team can arrange VIP mobile phlebotomy at your home or office within the UAE, and assist with insurance pre‑authorization for genetic testing. We accept major health insurance plans; please send a photo of your insurance card for verification.
UAE Regulatory & Data Privacy Adherence
Compliance & Accreditation Framework
- DHA Licensed Facility – License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) for quality management.
- Full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for patient data privacy.
- Adherence to Federal Law No. 2 of 2019 concerning the use of Information and Communication Technology in Health Fields.
- Informed consent and clinical safety following Federal Decree-Law No. 4 of 2016 on Medical Liability.
- All procedures aligned with DHA Clinical Pathology Standards and international ACMG guidelines.
Clinical & Logistical Metadata
| Test Name | NGS Glaucoma Genetic Panel (Blood) |
| Price (AED) | 3,200 AED |
| Turnaround Time | 45 working days |
| Sample Type / Matrix | Whole Blood (Peripheral Venipuncture) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available |
| Methodology Used | Next‑Generation Sequencing (NGS) with Orthogonal Sanger Confirmation |
| ICD-10-CM Code | H40.0 (Glaucoma Suspect), H40.1 (Primary Open‑Angle Glaucoma), Z15.89 (Genetic Susceptibility to Other Disease) |
| LOINC Code | 92855-7 – Glaucoma multi‑gene panel – Blood by Sequencing |
| DHA Facility License & Laboratory Address | License No. 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians